By: Christopher Parrella, Esq., CPC, CHC, CPCO
Parrella Health Law, Boston, Ma.
A Health Care Provider Defense and Compliance Firm
In a decisive move to uphold the integrity of federal healthcare programs, the U.S. Department of Justice (DOJ) announced a $1.67 million settlement with ASD Specialty Healthcare LLC (Besse Medical) for violating the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). This case underscores the government’s unyielding stance against illegal financial incentives in the healthcare supply chain.
The Allegations: Inventory Management Software as a Kickback Scheme
The DOJ alleged that ASD Specialty Healthcare LLC, a distributor of specialty medical products, used its inventory management system PODIS to entice ophthalmology practices into purchasing branded wet AMD drugs. Between May 2017 and November 2023, ASD allegedly offered this system at no cost to practices that agreed to purchase specific products, constituting an illegal kickback arrangement under federal law.
According to the AKS, providing “remuneration” — including free products or services — in exchange for referrals or drug purchases that Medicare, TRICARE, or the Department of Veterans Affairs covers is strictly prohibited. The government argued that these practices led to fraudulent claims being submitted to federal healthcare programs.
Federal Enforcement and Industry Accountability
Federal officials emphasized that financial inducements compromise medical judgment, inflate healthcare costs, and disadvantage ethical competitors. As Principal Deputy Assistant Attorney General Brian M. Boynton stated: “We will pursue kickbacks at all levels of the distribution chain to preserve the integrity of federal health care programs.”
The settlement highlights the DOJ’s use of the False Claims Act’s qui tam provisions, allowing whistleblowers to file lawsuits on behalf of the government. In this case, former Regeneron Pharmaceuticals Inc. employees filed the lawsuit, receiving $250,705.20 as part of the settlement.
Lessons for Healthcare Stakeholders
This settlement underscores several key lessons for healthcare companies:
- Compliance Oversight: Healthcare suppliers must monitor internal sales strategies and ensure compliance with AKS and FCA regulations.
- Transparency in Contracts: Any benefits or incentives offered to healthcare providers must be disclosed and comply with federal standards.
- Whistleblower Protections: Employees aware of unethical practices should understand their rights under the FCA’s whistleblower provisions.
Call to Action
Parrella Health Law remains committed to helping healthcare providers, suppliers, and distributors maintain compliance in this complex regulatory landscape. If you need expert guidance on AKS, FCA compliance, or responding to government investigations, contact Parrella Health Law today at 857.328.0382 or email Chris directly at cparrella@parrellahealthlaw.com.
Christopher A. Parrella, Esq., CPC, CHC, CPCO, is a leading healthcare defense and compliance attorney at Parrella Health Law in Boston. With extensive experience in healthcare law, he provides robust legal support in areas including regulatory compliance, audits, healthcare fraud defense, and reimbursement disputes. Christopher emphasizes client-centered advocacy, offering one-on-one consultations for personalized guidance. His proactive approach helps clients navigate complex healthcare regulations, ensuring compliant operations and defending against government investigations, audits, and overpayment demands.
Leave a Reply